The more I think about it, Peregrine has to partner. There's no other way PPHM can afford a PIII/PIV clinical trial -- and enrolment in a PIII/PIV is pretty much required before a company can be granted AA. The FDA may even require interim data from the PIII/PIV to grant the AA.
So AA cannot be something Oxford is counting on.
I agree with Firechief and Corporalagarn, Oxford has to be confident that a deal is afoot.
Market Data 
Markets 
AI
